Patent · US Active

Pharmaceutical combination of anti CEACAM6 and TIM3 antibodies

US12221479B2 · kind B2 · utility

0Cited by

6References

11Claims

0Family size

Assignees

BAYER HEALTHCARE LLC · DE
Deutsches Krebsforschungszentrum · DE

Inventors

Jörg Willuda · Berlin, DE
Mark Trautwein · Whippany, US
Rienk Offringa · Leiden, NL
Hans-Henning BÖHM · Heidelberg, DE
Philipp Beckhove · Heidelberg, DE

Key dates

Filing date	Dec 12, 2019
Grant date	Feb 11, 2025
Priority date	—
Expiry date	Mar 6, 2042

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/76
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present disclosure relates to combinations of at least two components, component A and component B, component A being anti-CEACAM6 antibody TPP-3310 and component B being an anti-TIM-3 antibody, preferentially cobolimab, MBG-453, BMS-986258, Sym-023, LY-3321367 or INCAGN-2390.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.